JP2024535110A5 - - Google Patents
Info
- Publication number
- JP2024535110A5 JP2024535110A5 JP2024519586A JP2024519586A JP2024535110A5 JP 2024535110 A5 JP2024535110 A5 JP 2024535110A5 JP 2024519586 A JP2024519586 A JP 2024519586A JP 2024519586 A JP2024519586 A JP 2024519586A JP 2024535110 A5 JP2024535110 A5 JP 2024535110A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- complement
- guanine
- uracil
- arhgef12
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163250492P | 2021-09-30 | 2021-09-30 | |
| US63/250,492 | 2021-09-30 | ||
| PCT/US2022/077176 WO2023056295A1 (en) | 2021-09-30 | 2022-09-28 | Treatment of glaucoma with rho guanine nucleotide exchange factor 12 (arhgef12) inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024535110A JP2024535110A (ja) | 2024-09-26 |
| JP2024535110A5 true JP2024535110A5 (cg-RX-API-DMAC7.html) | 2025-09-30 |
Family
ID=83996920
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024519586A Pending JP2024535110A (ja) | 2021-09-30 | 2022-09-28 | Ｒｈｏグアニンヌクレオチド交換因子１２（ＡＲＨＧＥＦ１２）阻害剤による緑内障の治療 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12577562B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4408535A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024535110A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240099232A9 (cg-RX-API-DMAC7.html) |
| CN (1) | CN118891050A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022357497A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3232251A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL311711A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023056295A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003280812A1 (en) * | 2002-11-18 | 2004-06-15 | Santen Pharmaceutical Co., Ltd. | REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND Beta-BLOCKER |
| US20090264533A1 (en) * | 2005-03-30 | 2009-10-22 | Richard Neubig | Methods and Compositions for Modulating RHO-Mediated Gene Transcription |
| AR057252A1 (es) * | 2005-12-27 | 2007-11-21 | Alcon Mfg Ltd | Inhibicion de rho quinasa mediada por arni para el tratamiento de trastornos oculares |
| GB201107176D0 (en) | 2011-04-28 | 2011-06-15 | Cxr Biosciences Ltd | Pyrrolnitrin derivatives |
| EP3866790A4 (en) * | 2018-10-15 | 2022-08-03 | Ocuphire Pharma, Inc. | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GLAUCOMA AND RELATED DISEASES |
| MX2021008797A (es) * | 2019-01-23 | 2022-01-31 | Regeneron Pharma | Tratamiento de afecciones oftalmicas con inhibidores de proteinas relacionadas a angiopoyetina 7 (angptl7). |
-
2022
- 2022-09-28 KR KR1020247014295A patent/KR20240099232A9/ko active Pending
- 2022-09-28 WO PCT/US2022/077176 patent/WO2023056295A1/en not_active Ceased
- 2022-09-28 US US17/936,244 patent/US12577562B2/en active Active
- 2022-09-28 AU AU2022357497A patent/AU2022357497A1/en active Pending
- 2022-09-28 CA CA3232251A patent/CA3232251A1/en active Pending
- 2022-09-28 EP EP22797214.8A patent/EP4408535A1/en active Pending
- 2022-09-28 CN CN202280075189.3A patent/CN118891050A/zh active Pending
- 2022-09-28 JP JP2024519586A patent/JP2024535110A/ja active Pending
- 2022-09-28 IL IL311711A patent/IL311711A/en unknown